Navigation Links
Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Date:9/11/2007

ANA598 demonstrates favorable preclinical antiviral, metabolic,

pharmacokinetic and preliminary toxicologic properties

SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) presented preclinical data today on ANA598, a non-nucleoside inhibitor of the HCV NS5B polymerase, during a poster session at the 14th International Symposium on Hepatitis C Virus and Related Viruses.

The report characterized the favorable antiviral, metabolic, pharmacokinetic and preliminary toxicologic properties that supported the decision announced in June to progress ANA598 to IND enabling studies and subsequent clinical evaluation expected to commence in the first half of 2008. ANA598 is a potent, low-nanomolar inhibitor of HCV genotype 1a and 1b replicons and has exhibited good metabolic stability properties in in vitro preclinical studies. It also does not significantly inhibit or induce cytochrome enzymes, indicating that the compound has a low likelihood of producing clinical drug-drug interactions. ANA598 was well tolerated in 14-day dose range finding (DRF) animal toxicology studies at all doses tested (1 to 1000mg/kg). In in vivo preclinical studies designed to be predictive of potential human doses, trough plasma concentrations of ANA598 24 hours post dosing exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition at doses corresponding to estimated human doses. The EC95 is the concentration required to suppress hepatitis C viral RNA levels by 95% in the replicon assay.

"We are pleased with the ANA598 plasma exposures we have observed in animal studies at doses that were well tolerated for 14 days," said Steve Worland, Ph.D., President and Chief Executive Of
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
2. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/4/2015)... Ltd. (NASDAQ: ELOS ), a leading global aesthetic device ... ended June 30, 2015. Second Quarter ... , Revenue of $73.5 million, up 14% year-over-year, or ... grew 45% year-over-year. , International sales grew 8% year-over-year, ... the EMEA region and 25% product growth in the Asia-Pacific ...
(Date:8/3/2015)... 4, 2015   The Intellectual Property and ... leading provider of intelligent information for businesses and ... CMR Pharmaceutical R&D Factbook , the biopharmaceutical industry,s ... around declines in R&D, the analysis identifies a ... milestone and forecasts sales to reach $1.3 trillion ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Pharma Sales to Grow Beyond $1 Trillion 2
... HAMBURG , Feb. 3 , The International ... a global teleconference that will: , Detail the launch of ... its symposium in Hamburg being held February 5-6, ... develop a comprehensive, evidence-based consensus on the use of NPWT; ...
... BALTIMORE , Feb. 2 Celsis In Vitro, Inc. ... lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical ... District of Illinois in Chicago .  XenoTech and ... that certain processes and methods performed by XenoTech associated with its ...
Cached Medicine Technology:The International Negative Pressure Wound Therapy Expert Panel to Announce Results of Inaugural Symposium in Hamburg 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
(Date:8/4/2015)... ... August 04, 2015 , ... One of the nation’s leading experts in ... book, The Pain Antidote , which provides strategies for people who suffer from ... Chronic Pain Treatment Program, wrote the book in conjunction with Katherine Ketcham, an author ...
(Date:8/4/2015)... ... 2015 , ... Buckeye Health Plan is reminding parents to ... covered for members under the Healthchek program . , “Many schools have ... immunizations may not be allowed to attend when school begins in August,” said ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... with full examination now offered by the world renowned Beverly Hills facelift ... facial appearance through cosmetic surgery techniques helps individuals to achieve an outer appearance ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics heaven,” “mecca ... experience inside Naimie’s Beauty Center in LA. Now MENAJI is part of that experience ... , Naimie’s Beauty Center has been a favorite of makeup artists and hair pros ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
Breaking Medicine News(10 mins):Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2
... and Hollywood elite celebrated the launch of the ... Biomedical Skin Treatments - ... Fisher and beauty industry veteran Paul Scott Premo ... the heart of Los Angeles. (Photo: ...
... but some risks tied to dose strength, study says ... improves walking ability in some people with multiple sclerosis. , ... 18 to 70, the participants were randomly assigned to receive ... day for 14 weeks. The patients, walking speed was assessed ...
... 27 /PRNewswire-Asia/ -- Winner Medical Group Inc.,(OTC ... a leading,manufacturer in the Chinese medical dressing ... that the European Patent Office has decided ... to Winner Medical. The,following are specifically covered ...
... (Nasdaq: ENDP ) announced today that it ... and market the investigational drug axomadol in the United ... entity discovered by Grunenthal and currently in Phase II ... chronic pain and diabetic peripheral neuropathic pain.Under the license ...
... to drive solid cash net income growthHAMILTON, Bermuda, Feb. 27 ... announced its results for the quarter and year ended December ... 2008 totaled $242.5 million, an increase of 6.5%, over the ... 2008 totaled $938.1 million, an increase of 4.3%, over the ...
... 27 Fourth quarter of 2008 as compared to ... UHT ) announced today that for the quarter ... or $.07 per diluted share, as compared to reported net ... the comparable quarter in the prior year. Included in net ...
Cached Medicine News:Health News:Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo 2Health News:Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo 3Health News:Drug Improves Mobility in Some MS Patients 2Health News:Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method 2Health News:Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method 3Health News:Endo Licenses Novel Pain Therapy from Grunenthal 2Health News:Endo Licenses Novel Pain Therapy from Grunenthal 3Health News:Endo Licenses Novel Pain Therapy from Grunenthal 4Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 2Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 3Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 4Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 5Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 6Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 7Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 8Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 9Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 10Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 11Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 12Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 13Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 14Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 15Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 16Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 17Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 18Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 11
... variety of colors and classic shapes, ... designed with elegant jewel detail. With ... that are made from the same ... our fine timepieces, Timex branded frames ...
... captures the whimsy, charm and cutting edge ... design is inspired by Cynthia Rowley's creativity, ... from the Kenmark Group and B Robinson ... features eight optical and four sunwear designs ...
... collection offers a broad and definitive line ... value-minded consumer. The core line is a ... age and price sensitivity. The common theme ... high quality craftsmanship and a competitive price-versus-value ...
... The new Eyewear ... lifestyle proposition, encompassing elegance, ... well as a dedication ... Mirroring key attributes of ...
Medicine Products: